Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer

被引：0
|
作者：
Trarbach, T. [1 ,2 ]
Schuette, K. [1 ,2 ]
Stoehlmacher, J. [1 ,2 ]
Goekkurt, E. [1 ,2 ]
Guenther, H. [1 ,2 ]
Ubbelohde, U. [1 ,2 ]
Stroszczynski, C. [1 ,2 ]
Ehninger, G. [1 ,2 ]
Folprecht, G. [1 ,2 ]
机构：
[1] W German Canc Ctr, Essen, Germany
[2] Univ Hosp Carl Gustav Carus, Dresden, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15025
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Gunnar Folprecht
    Susanne Hamann
    Katharina Schütte
    Tanja Trarbach
    Jan Stoehlmacher-Williams
    Gerhard Ehninger
    BMC Cancer, 14
  • [2] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Folprecht, Gunnar
    Hamann, Susanne
    Schuete, Katharina
    Trarbach, Tanja
    Stoehlmacher-Williams, Jan
    Ehninger, Gerhard
    BMC CANCER, 2014, 14
  • [3] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [4] SECOND-LINE CHEMOTHERAPY AFTER FIRST-LINE IRINOTECAN, OXALIPLATIN AND 5-FU/LV (FOLFOXIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Marcucci, L.
    Cupini, S.
    Masi, G.
    Allegrini, G.
    Cerri, E.
    Loupakis, F.
    Ricci, S.
    Brunetti, I.
    Fontana, E.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 60 - 60
  • [5] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
    Masi, G
    Allegrini, G
    Marcucci, L
    Cupini, S
    Brunetti, I
    Fontana, E
    Ricci, S
    Cerri, E
    Barbara, C
    Falcone, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [6] Randomised comparison of 5-FU/folinic acid plus irinotecan (FOLFIRI) and irinotecan plus oxaliplatin (IROX) in first-line therapy of metastatic colorectal cancer (CRC):: the fire-trial
    von Weikersthal, L. Fischer
    Schalhorn, A.
    Quietzsch, D.
    Maubach, P. A.
    Schlimok, G.
    Lambertz, H.
    Weigang-Koehler, K.
    Schultz, M.
    Schlag, R.
    Grundeis, M.
    Heinemann, V.
    EJC SUPPLEMENTS, 2005, 3 (02): : 167 - 167
  • [7] Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    Van Cutsem, E.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Nippgen, J.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer
    Choi, I
    Oh, D.
    Kim, B.
    Lee, K.
    Kim, J.
    Lee, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 51 - 51
  • [9] FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.
    Glenjen, Nils
    Hammerling, Katrin
    Hatlevoll, Ingunn
    Smaland, Rune
    Hauge, Petra Weber
    Eide, Geir Egil
    Sorbye, Halfdan
    Dahl, Olav
    Frykholm, Gunilla
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [10] First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
    Masi, G.
    Marcucci, L.
    Loupakis, F.
    Cerri, E.
    Barbara, C.
    Bursi, S.
    Allegrini, G.
    Brunetti, I. M.
    Murr, R.
    Ricci, S.
    Cupini, S.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 (08) : 1249 - 1254
12345